The zebrafish has many advantages as a vertebrate model organism and has been extensively used in the studies of development. Its potential as a model in which to study tumour suppressor and oncogene function is now being realized. Whilst in situ hybridization of mRNA has been well developed in this species to study gene expression, antibody probes are in short supply. We have, therefore, generated a panel of anti-zebrafish p53 monoclonal antibodies and used these to study the p53 response in zebrafish embryos. By immunohistochemistry, we show that the exposure of zebrafish embryos to p53-activating agents such as R-roscovitine and c-irradiation results in the accumulation of p53 protein in the gut epithelium, liver and pancreas. A combination of R-roscovitine and c-irradiation results in massive p53 induction, not only in the pharyngeal arches, gut region and liver but also in brain tissues. Induction of apoptosis and expression of p53 response genes are seen in regions that correspond to sites of p53 protein accumulation. In contrast, although zebrafish tp53 M214K mutant embryos showed a similar accumulation of p53 protein, a complete lack of a downstream p53-dependent response was observed. In this system the p53 gene is identified as a p53-responsive gene itself. Our results demonstrate that zebrafish p53 protein can readily be induced in embryos and detected using these new antibody tools, which will increase the usefulness of zebrafish as a model in compound-based screening for novel drugs in cancer research.
Introduction
The tumour suppressor p53 is one of the most studied proteins in cellular stress response pathways. These pathways, which lead to cell cycle arrest, DNA repair, cellular senescence and apoptosis, serve to protect the organism from DNA-damaging stimuli. As reviewed extensively, p53 is mutated or lost in 50% of all human cancers (Hollstein et al., 1991; Levine et al., 1991; Greenblatt et al., 1994) . In many human tumours, the mutant p53 protein has an extended half-life and high levels accumulate in the nucleus and can be detected immunohistologically.
The p53 gene is highly conserved in evolution, and has been studied in a wide range of species from human to flies and worms (Soussi and May, 1996; Jin et al., 2000; Sutcliffe and Brehm, 2004) . The zebrafish is an excellent vertebrate model for embryological and genetic analysis, and is now the most widely used teleost species in biomedical research. In combination with its use in carcinogenesis assays (Stanton, 1965) , these attributes make zebrafish an attractive model system for studying cancer genetics (Stern and Zon, 2003) . Studies have shown that exposure of zebrafish to carcinogens induces a significant number and variety of neoplasms (Spitsbergen et al., 2000) . From a histopathology point of view, the fish neoplasms are remarkably similar to human cancer (Spitsbergen and Kent, 2003) and it is likely that many of the pathways involved in zebrafish tumorigenesis will be germane to the study of human neoplasms. However, the use of the zebrafish as a model organism in p53 signalling pathway analysis has been hampered by a lack of reagents. Previous work has mainly been dependent upon in situ hybridization of mRNA to study gene expression and apoptosis detection by TUNEL labeling (Langheinrich et al., 2002) . The availability of antibodies against zebrafish p53 protein would, therefore, offer a prospect of a powerful system for identification of novel cancer genes and for the cancer drug discovery. In this present study, we describe the production and characterization of monoclonal antibodies directed against zebrafish p53. We demonstrate that the monoclonal antibodies are useful for immunoblotting and immunohistochemistry in zebrafish embryos. We show that intense nuclear p53 staining can be induced by both ionizing radiation and chemotherapeutic drugs in this model organism.
Results

Purification of zebrafish p53 fusion proteins
To generate the recombinant antigen for immunization, tp53 cDNA of the zebrafish (Danio rerio) was generated by PCR and expressed with a histidine tag in Escherichia coli. The use of the Overnight Express Autoinduction system (Novagen) permitted high levels of His-p53 fusion protein expression without the need to monitor cell growth ( Figure 1, lane 2) . Cell fractionation studies, however, show that the His-p53 fusion protein is highly insoluble and is found mainly in the bacterial inclusion bodies ( Figure 1a , lane 4) from which it could be purified ( Figure 1a , lane 5). MALDI mass spectroscopy analysis of this band showed a high return score for zebrafish p53 protein (data not shown). The molecular weight size of 53 kDa contrasts significantly with the calculated mass of 41.9 kDa based on the amino acid sequence of zebrafish p53, this discrepancy could be due to the presence of high proline residue content in p53 proteins and is similarly seen in the apparent molecular weight of human and murine p53 (Oren, 1985) .
Production and screening of the anti-p53 zebrafish antibodies A total of 900 mouse hybridoma colonies were obtained after the fusion of splenocytes from immunized mice and myeloma cells and these were subjected to rigorous screening designed to identify antibodies suitable for immunohistochemistry on formalin-fixed paraffin-embedded tissues. After initial screening, 47 positive clones were then further characterized by immunohistochemical staining of p53-transfected H1299 cells, stained as sections of cell pellets fixed in formalin and embedded in agarose. Supernatant from 10 hybridoma clones showed strong, specific cell staining (Figure 1b) , and these were single-cell cloned and further analysed.
p53-transfected H1299 cell lysates were immunoprecipitated with monoclonal antibodies ZFp53-5.1, ZFp53-9.1 and a negative control antibody to a haemagglutinin (HA) epitope tag. Immunoblots of these immunoprecipitates were then probed with a rabbit antizebrafish p53 polyclonal antibody, ZF-R18, also generated in this study. Similarly, ZF-R18 was used to immunoprecipitate the cell lysate, followed subsequently by probing the immunoblots with monoclonal antibodies ZFp53-5.1, ZFp53-9.1 and the anti-HA epitope antibody. The results show that the monoclonal antibodies and the ZF-R18 polyclonal antibody were able to capture p53 from the cell extract (Figure 1c) , thus demonstrating the sensitivity and specificity of zebrafish p53 protein immunoprecipitation by these antibodies.
Using a set of overlapping zebrafish p53 peptides, the epitopes of the 10 monoclonals were mapped (Figure 2 ). Of the 10 monoclonals characterized, 6 were of the IgG isotype while the remaining four were IgM isotype (Table 1, column 2) . The antibodies were also tested for cross-reactivity and specificity on four human breast cancer cell lines. The BT474, BT549 and T47D cell lines Figure 1 Expression of recombinant zebrafish p53 in Escherichia coli followed by generation and characterization of p53 monoclonal antibodies. (a) Purification of His10-tagged recombinant zebrafish p53 protein. Aliquots of purification extracts separated by electrophoresis on 4-12% gradient polyacrylamide SDS gel show whole cell lysates containing pET19b (lane 1) and pET19b-p53 (lane 2), soluble protein extract following Ni 2 þ -charged chromatography purification (lane 3), insoluble pellet (inclusion bodies) before chromatography purification (lane 4) and purified protein obtained after the inclusion body material was subjected to Ni 2 þ -charged chromatography purification (lane 5). Arrow indicates the position of the p53 fusion protein. (b) Screening and selection of zebrafish p53 hybridoma clones by immunoperoxidase staining of agarose-embedded formalin-fixed cell pellet sections. The monoclonal antibody ZFp53-5.1 showed negative staining in untransfected H1299 cells (left panel), whereas strong cell staining was seen on sections of p53-transfected H1299 cells (right panel). Scale bar ¼ 100 mm. (c) Immunoblots of immunoprecipitates from p53-transfected H1299 cell extracts. ZFp53-5.1 (lane 2) and ZFp53-9.1 (lane 4) monoclonal antibodies are able to immunoprecipitate protein recognized on immunoblots probed by the rabbit antiserum to zebrafish p53, ZF-R18 (lanes 1-4). Similarly, ZF-R18 immunoprecipitates p53, which is recognized on immunoblots probed by ZFp53-5.1 (lanes 5 and 6) and probed by ZFp53-9.1 (lanes 7 and 8). Control samples (lanes 1, 3, 5 and 7) immunoprecipitated with an antibody to haemaglutinin (HA) are negative when immunoblotted with ZF-R18 (lanes 1 and 3), ZFp53-5.1 (lane 5) or ZFp53-9.1 (lane 7). M r values of the molecular weight markers are indicated on the left (kDa). carry a mutant p53 gene in comparison to the wild-type p53 gene in the MCF7 cell line (Bartek et al., 1990) . None of the new zebrafish monoclonal antibodies recognized human p53 in this assay by immunoblotting assays. Immunoblotting of total protein extracts from these cell lines did reveal that three of the monoclonals (Table 1 , column 4) displayed cross-reactivity with other proteins in the cell lines. The band positions of these proteins are not indicative of the human p53 protein (data not shown). All the three cross-reactive monoclonals, namely, ZFp53-1.1, ZFp53-4.1 and ZFp53-10.1 belong to the IgM isotype. Immunoblots of whole cell extracts of the p53-transfected H1299 cell line showed that all the monoclonal antibodies were able to detect the p53 protein (Table 1 , column 5). With the exception of ZFp53-10.1, all the antibodies showed positive immunoperoxidase staining when immunocytochemistry was performed on p53-transfected H1299 cells (Table 1 , column 6).
Having established the specificity of the monoclonal antibodies, the ability of the antibodies to detect p53 protein in zebrafish embryos was investigated. To induce p53 protein, 2-day post-fertilization (dpf) zebrafish embryos were treated overnight with 50 mM R-roscovitine, a cyclin-dependent kinase inhibitor that can efficiently stabilize and activate nuclear p53 by inducing downregulation of mdm2 expression at both protein and mRNA levels in human cell systems (Kotala et al., 2001; Lu et al., 2001) . Preliminary immunohistochemistry staining showed that monoclonal antibodies ZFp53-2.1, ZFp53-5.1, ZFp53-6.1 and ZFp53-9.1 were able to show strong positive nuclear staining in certain regions of the embryos ( Figure 2 Epitope map of the zebrafish p53 monoclonal antibodies generated in this study. Functional domains of p53 protein are indicated as annotated in GenBank accession number P79734 by boxes TA (transactivation domain), DNA-BD (DNA binding domain), BNLS (bipartite nuclear localization signal), OD (oligomerization domain) and BR (basic C-terminal region). Amino acid numbers for both functional domains and antibody epitopes are indicated. The arrows indicate the location of the N terminal amino acid of the mapped epitope. Immunoblotting of the mAbs to test for cross-reactivity and specificity in BT474, BT549, T47D and MCF7 human cancer cell lines, which express elevated levels of p53. 'Yes' indicates the mAbs that show bands sizes on the immunoblots that are not indicative of human p53 protein, 'No' indicates non-reactivity with the human cancer cell lines. c Detection of p53 in immunoblots of zebrafish p53-transfected H1299 cell extract using the mAbs made in this study.
d Immunocytochemistry staining was performed on p53-transfected H1299 cells fixed in formalin. Cells were stained using DAB to detect immunoperoxidase activity, which indicates the level of detection specificity of the mAbs.
e Immunohistochemistry staining of 2-day post-fertilization zebrafish wild-type embryos that were treated overnight with 50 mM R-roscovitine. Embryos were fixed and stained as described in Materials and methods. + indicates an immunoreactivity response towards zebrafish p53 by the mAbs; À shows no reactivity.
ZFp53-5.1 monoclonal antibody as a reagent for zebrafish study in the p53 pathway As the monoclonal antibody ZFp53-5.1 showed the cleanest and most intense nuclear staining pattern, this antibody was selected for use in pharmacological experiments on zebrafish embryos. The expression of p53 protein in zebrafish wild-type and tp53 M214K mutant embryos was examined by immunoblotting. The tp53 M214K mutant line (Berghmans et al., 2005) has a mutation that affects a region of the p53 protein involved in binding DNA at p53-specific consensus sequences. To induce p53 protein expression, embryos at 2 dpf were exposed for 12 h to 50 mM R-roscovitine or exposed to a dose of 24 Gy g-irradiation and examined 12 h later. In a separate experiment, embryos were given a dose of 24 Gy g-irradiation and incubated for 10 h in medium containing 50 mM R-roscovitine before analysis. Immunoblotting results showed that the ZFp53-5.1 monoclonal antibody detected a protein band of 50 kDa in both the wild-type ( Figure 3a ) and tp53 Figure 3a , lane 8) migrated slower than the p53 present in the zebrafish embryo, due to the presence of the epitope tags artificially incorporated with these sequences. The intensity of the p53 band was similar for all the samples regardless of whether the embryos had been exposed to R-roscovitine or irradiated. This indicates that p53 protein, as detected by this antibody and using these extraction and immunoblotting conditions, was not significantly induced by the treatments. To confirm that protein expression could be manipulated at all, one-cell stage wild-type embryos were injected with a p53 expression-inhibiting morpholino and incubated for 2 days in buffered salt water medium before total protein extraction; in this case, immunoblotting analysis showed a dramatic decrease of p53 protein ( Figure 3a , lane 2) as compared to untreated embryos ( Figure 3a , lane 1), thus confirming the specificity of the antibody in immunoblotting.
Induction of p53 by R-roscovitine was examined in situ by immunohistochemistry. Zebrafish embryos were treated with 50 mM R-roscovitine to stabilize and activate p53 protein expression, with or without prior injection of p53 morpholino at the zygote stage. Untreated embryos, which had been injected with p53 morpholino, did not show any staining (Figure 4a ). Embryos injected with a negative control morpholino gave strong nuclear staining in the gut epithelium after the induction of p53 protein expression by R-roscovitine exposure (Figure 4b , inset). The nuclear staining in the intestinal epithelium was not seen when p53 morpholino-injected embryos were treated with R-roscovitine ( Figure 4c ). This clearly demonstrates that R-roscovitine alters p53 protein expression in zebrafish embryos and this alteration can be detected by monoclonal antibody ZFp53-5.1 using immunohistochemistry to stain the tissues in situ. The failure to detect this effect by immunoblotting may be due to the relatively small number of cells responding in the context of the whole animal, so that biochemically the induced protein is highly diluted.
Expression of p53 in developing zebrafish tissues
To take advantage of the histological resolution afforded by these new reagents, the monoclonal antibody ZFp53-5.1 was used to look at the expression of p53 in a range of tissues in zebrafish embryos and to see how different tissues might respond to stress induced by drug treatment and g-irradiation. Untreated early embryos (2 dpf) do not show any staining (Figure 4d ). However, when 2 dpf embryos were exposed overnight to 50 mM R-roscovitine, strong nuclear staining was induced in the epithelial lining of the developing gut and in the liver (Figure 4e ). Sagittal sections revealed that the nuclear staining reflecting p53 accumulation in the gastrointestinal system extended from the pharyngeal arches to the cloaca. There was also a strong increase of p53 immunoreactivity in the retina of the developing eye when compared to untreated embryos ( Figure 4d ). To see the effects of radiation-induced stress versus chemical-induced stress, the expression of p53 protein in zebrafish embryos after g-irradiation was examined. Similar to the effects of R-roscovitine exposure, embryos exposed to 24 Gy of g-irradiation showed p53 Figure 3 Detection of p53 protein expression by immunoblotting of total protein extracts of 3 dpf zebrafish wild-type embryos and zebrafish tp53
M214K mutant embryos using ZFp53-5.1 monoclonal antibody. Primary antibody was used at a concentration of 1 mg/ml followed by detection using an anti-mouse secondary antibody at 1:1000 dilution and chemiluminescence substrate. (a) p53 response in 3 dpf zebrafish wild-type embryos upon exposure to the following treatments was labelled accordingly: untreated (lane 1), p53-morpholino (lane 2), 50 mM R-roscovitine (lane 3), 24 Gy g-irradiation (lane 4) and combination of 24 Gy g-irradiation followed by addition of 50 mM R-roscovitine (lane 5). Lanes 6-8 denote controls of untransfected H1299, p53-transfected H1299 and purified zebrafish p53 fusion protein respectively. (b) p53 response in zebrafish tp53 M214K mutant embryos upon exposure to the following treatments: untreated (lane 1), 50 mM R-roscovitine (lane 2), 24 Gy g-irradiation (lane 3) and combination of 24 Gy g-irradiation followed by the addition of 50 mM R-roscovitine (lane 4). Lanes 5-7 denote controls of untransfected H1299, p53-transfected H1299 and purified zebrafish p53 fusion protein respectively. Proliferating-cell nuclear antigen antibody was used to verify equal loading amounts of total protein extract of 10 mg zebrafish embryo. No or low levels of p53 protein induction was seen in both wild-type and mutant zebrafish embryos following the exposure with p53-activating agents.
protein expression in the pharyngeal arches and posteriorly along the length of the gastrointestinal tract (Figure 4f ), but not discernibly in the retina. However, when the g-irradiated embryos were additionally exposed to R-roscovitine for 10 h, there was a substantial induction of p53 immunoreactivity, not only in the gastrointestinal tract but also in parts of the developing central nervous system; staining was now clearly visible in the tectum, cerebellum and myelencephalon of the developing brain and in the ganglion cell layer of the eye (Figure 4g ). Importantly, immunohistochemical examination of tp53 M214K mutant embryos also revealed a dramatic increase in p53 immunoreactivity ( Figure 5 ). In contrast to the wild-type embryos, untreated mutant embryos also displayed a few foci of above-background p53 immunoreactivity, most noticeably in the ethmoid plate at the front of the oral cavity and also in the liver (Figure 5a ). The mutant fish showed a clear induction of p53 immunoreactivity in response to both chemical ( Figure 5b ) and radiation (Figure 5c ) stress. Though this was broadly similar in distribution to that seen in the wild-type embryos, the response to radiation was notably stronger.
To assess whether the inducibility of p53 changed with increasing age of the embryos, 5 dpf wild-type embryos were exposed overnight with 50 mM R-roscovitine. Sagittal sections showed that in comparison to 2 dpf embryos treated with the same compound (Figure 4e ), the induction of p53 is much more restricted in these older embryos, with significant staining now confined to the epithelial lining of the intestinal tract (Figure 6b ). Much less immunoreactivity is seen in the liver, for example, of 5 dpf embryos exposed to Rroscovitine than is seen in the 2 dpf embryos after the same treatment (compare Figure 4e with 6b). Untreated 5dpf embryos do not show any p53 immunoreactivity using the same antibody (Figure 6a ).
p53-activating agents upregulate p53-dependent transcriptional responses in wild-type but not tp53 M214K mutant embryos To determine whether this induced p53 is truly functional, evidence of a downstream transcriptional response was sought. Whole-mount in situ hybridization was performed to examine the expression of downstream p53-dependent response genes on embryos exposed to p53-activating agents. These target genes included bax, a proapoptotic factor (Reed, 1999) ; cyclin G1 and p21 WAF1/CIP-1 that have crucial roles in cell cycle Figure 4 Immunohistochemical staining of p53 using ZFp53-5.1 hybridoma supernatant on formalin-fixed transverse (a-c) and sagittal (d-g) sections of 3 dpf zebrafish wild-type embryos. Insets show the intensity of nuclear staining in the intestinal epithelium (a) No staining pattern was observed in the gut (gt) for p53 morpholino-injected embryos that are untreated with R-roscovitine. (b) Strong nuclear staining pattern was observed in the gut of embryos that were injected with negative control morpholino and subsequently exposed to 50 mM R-roscovitine overnight at 2 dpf. (c) An overall absence of nuclear staining in the gut of p53 morpholino-injected embryos that were exposed to 50 mM R-roscovitine overnight at 2 dpf. (d) Untreated zebrafish embryos show no p53 staining even in the epithelial lining of the developing gut. (e) After overnight treatment with 50 mM R-roscovitine, strong nuclear staining due to p53 accumulation was seen in the gut (gt) epithelium, pancreas (p), liver (li), pharyngeal arches (pa), basal plate (bp) and cells (rc) of the retina tissue. A moderate amount of staining was also seen in the myotomes. (f) When 2 dpf embryos were exposed to 24 Gy of g-irradiation, p53 immunoreactivity was seen in the pharyngeal arches (pa), liver (li), stomach (st), intestine (in), tectum (tec), cerebellum (ce) and myelencephalon (my). (g) When the g irradiated embryos were later subjected to 50 mM R-roscovitine treatment for 10 h, a more extensive increase in p53 expression was observed in the same areas as seen in g irradiated only embryos. Furthermore, other tissues such as the ganglion cell layer (gcl), cells (rc) of the developing eyes and parts of the developing central nervous system such as telencephalon (tel) and basal plate (bp) also displayed strong nuclear staining indicative of p53 immunoreactivity. Scale bar ¼ 100 mm.
arrest (Ball, 1997; Zhao et al., 2003) and mdm2 that forms part of an autoregulatory feedback loop with p53 (Alarcon-Vargas and Ronai, 2002) . All four p53 target genes showed transcriptional upregulation in the wildtype embryos treated with p53-activating agents, most notably in the tectum and digestive organs (Figure 7 ). These regions also displayed an increase in p53 transcript levels (Figure 7i ). In the tp53 M214K mutant embryos, however, no such response can be seen.
The activity of caspase-3 was measured in zebrafish embryos after exposure to p53-activating agents.
Caspase-3 activation was seen most significantly in wild-type embryos treated with 50 mM R-roscovitine and a combination of 24 Gy g-irradiation and 50 mM Rroscovitine treatment (Figure 8a ). In contrast, tp53 M214K mutant embryos failed to show any increase in caspase-3 activity beyond the basal level as seen in untreated embryos. Similarly, TUNEL assays to detect apoptotic cells showed massive apoptosis in the head region and digestive organs of wild-type embryos that were treated with p53-activating agents (Figure 8b ). The increase in apoptotic response in these embryos correlates well with the levels of caspase-3 activity seen (Figure 8a ). The tp53 M214K mutant embryos, on the other hand, showed baseline apoptotic staining similar to untreated embryos.
Discussion
To open up a new portal of p53 research in zebrafish, we have made monoclonal antibodies to zebrafish p53 and established assays to study p53 expression in zebrafish tissues. In total, 10 zebrafish p53 monoclonal antibodies have been generated and characterized. One of these, that is, ZFp53-5.1, has been used here in a first series of experiments to describe p53 induction in zebrafish tissues.
The ZFp53-5.1 mouse monoclonal antibody is able to detect zebrafish p53 protein in both untreated wild-type embryos and tp53 M214K mutant embryos in immunoblots. However, treatment of both types of embryos with p53-activating agents revealed no increase in the p53 accumulation compared to untreated samples (Figures Immunohistochemical staining of p53 using ZFp53-5.1 hybridoma supernatant on formalin-fixed and sagittal sections of 3 dpf zebrafish tp53 M214K mutant embryos. (a) Untreated embryos showed a slight p53 immunoreactivity in the ethmoid plate (ep) above the oral cavity and liver (li). (b) After overnight treatment with 50 mM R-roscovitine, strong nuclear staining because of the p53 accumulation was seen in the gut (gt) epithelium, liver (li), pharyngeal arches (pa) and basal plate (bp). (c) When 2 dpf embryos were exposed to 24 Gy of g-irradiation, a strong p53 immunoreactivity was seen in the pharyngeal arches (pa), liver (li) and tectum (tec). (d) A combination of 24 Gy of g-irradiation and 50 mM R-roscovitine treatment showed the results similar to wildtype embryo (Figure 4g) . Scale bar ¼ 100 mm.
Detection of the p53 response in zebrafish embryos
K-C Lee et al 3a and b). In contrast, immunohistochemical analysis showed a clear and tissue specific induction of p53. When untreated, neither wild-type nor tp53 M214K mutant zebrafish embryos show any significant immunohistochemical staining. In situ hybridization of p53 mRNA had shown that zebrafish p53 transcripts are present and most abundant in zygotes and early cleavage embryos less than 1 h after fertilization, thereafter declining to barely detectable levels at 48 h (Cheng et al., 1997) . In this study, early embryos at 2 dpf were subjected to p53-activating drugs overnight, followed by immunohistochemical staining. Exposure to R-roscovitine overnight produced a significant, but highly tissuespecific, induction of p53 protein expression (Figures 4e  and 5b ). The susceptibility of the gut lining cells to p53 induction by small molecules makes this an excellent method for screening new anticancer drugs, whereby potential chemotherapeutic drugs can be added directly to the medium in which the fish are living for direct uptake, and the effect is subsequently analysed in tissue sections by immunohistochemistry using ZFp53-5.1 antibody.
Embryos exposed to g-irradiation developed p53 immunoreactivity in the gut and other tissues including the liver but not detectably in the eyes. The study of p53 induction in tissues of irradiated adult mice showed that some tissues display an increased accumulation of p53 after irradiation, while other tissues such as liver showed no response (Midgley et al., 1995) . Thus, similar to the situation in mammals, the induction of p53 and the response to p53 in zebrafish appear to be tightly regulated in a tissue-specific manner and is also dependent on the nature of the inducing signal. Using whole-mount in situ hybridization of zebrafish embryos during somitogenesis, earlier studies showed a higher expression of p53 mRNA in tectum and retina but not in myotomes (Thisse et al., 2000) . We also observed an increase in p53 protein expression in the retinal epithelium of 2 dpf embryos upon exposure to R-roscovitine (Figure 4e ). It is also interesting to note that the tissue-specific p53 protein expression varies with the age of the embryos. In comparison to 2 dpf embryos exposed to R-roscovitine (Figure 4e ), 5 dpf-exposed embryos showed significant p53 induction now confined Figure 7 Whole-mount in situ hybridization to examine the expression of p53 response genes in wild-type (wt) and tp53 M214K mutant (mut) embryos exposed to the combination of 24 Gy g-irradiation and 50 mM R-roscovitine (24 Gy þ 50 mM Ros) treatment at 2 dpf. Digoxygenin-labeled antisense probes against bax (a and b), cyclinG1 (c and d), mdm2 (e, f and k), p21 WAF1/CIP-1 (g and h) and p53 (i and j) reveal widespread expression of p53-response genes in the tectum (tec) and digestive organs (do) of treated wild-type embryos compared to untreated wild-type embryos (k). The mutant embryos show lack of upregulation of downstream target genes after treatment. Control sense probes were used for all hybridizations and one is shown as an example for a mutant embryo (l).
to the gut region (Figure 6b ). All these observations may indicate a spatial-and temporal-specific regulation of p53 in zebrafish.
Subsequent exposure of pre-irradiated zebrafish embryos to R-roscovitine resulted in a dramatic increase of p53 accumulation in more tissues of the embryo. This massive increase of p53 could be due to synergistic effects of R-roscovitine and g-irradiation, although again, no such synergism was detectable by immunoblotting. A recent study demonstrated that R-roscovitine and Nutlin-3, an inhibitor of human p53-mdm2 interaction (Vassilev et al., 2004) , show pharmacological synergism on several neuroblastoma cell lines, causing p53 stabilization and increased levels of apoptosis in Figure 8 Detection of p53-dependent apoptosis in zebrafish wild-type (wt) embryos and its absence in tp53 M214K mutant (mut) embryos after exposure with p53-activating agents. (a) Caspase-3 activation is seen in wild-type embryos upon the treatment with 50 mM R-roscovitine (50 mM Ros), 24 Gy of g-irradiation (24 Gy) and combination of 24 Gy g-irradiation and 50 mM R-roscovitine (24 Gy þ 50 mM Ros). In contrast, tp53
M214K mutant embryos do not show any increase in caspase-3 activity upon the treatment establishing that it is p53-dependent. (b) Similarly, TUNEL assay shows widespread apoptosis in the head region and digestive organs of wild-type (wt) embryos that were exposed to p53-activating agents. No noticeable increase in apoptosis was seen in tp53 M214K mutant (mut) embryos for all treatments. Results are representative of three independent experiments. All embryos are shown in sagittal view with the head to the left.
Detection of the p53 response in zebrafish embryos K-C Lee et al cultured cells (Ribas et al., 2006) and our results are consistent with this concept of synergism between p53-inducing signals.
The tp53 M214K mutation is positioned between other known missense mutation hot-spots in the DNAbinding domain of human p53 gene (Olivier et al., 2002) and is an example of a DNA contact mutation. All DNA contact mutations examined so far were found to inhibit or completely block sequence-specific DNA binding to p53-specific consensus sequences, but to have only limited and locally restricted consequences on the stability and conformation of the entire p53 protein (Cho et al., 1994) . Irradiated zebrafish tp53 M214K mutant embryos do not undergo apoptosis and failed to upregulate p21 gene expression (Berghmans et al., 2005) . Whole-mount in situ hybridization and TUNEL assays performed in this study confirm this observation. However, since the overall structural integrity of the mutated p53 protein is not compromised, it comes as no surprise that the ZFp53-5.1 monoclonal antibody can detect both the wild-type and mutated forms of p53 protein by immunohistochemistry.
Immunohistochemistry did not reveal any major differences in p53 immunoreactivity between wild-type and tp53
M214K mutant embryos exposed to p53-activating agents. Thus, mutant p53 is broadly subject to the same upstream regulation of its accumulation and distribution as the wild-type protein. One striking observation, however, is that the mutant embryos tend to show stronger p53 immunoreactivity compared to wild-type embryos, especially for untreated and g-irradiated embryos. Data from knock-in mice models with p53 hot-spot missense mutations showed that tumours from these mice exhibited high levels of p53 protein (Lang et al., 2004; Olive et al., 2004) . In contrast, the surrounding normal tissues of these mice do not show increased levels of p53, thus implying that mutant p53 is inherently unstable and that tumour-specific changes stabilize mutant p53. Here, we show that mutant p53 is stabilized by R-roscovitine and ionizing radiation with the same tissue type specificity as the wild-type protein. Our immunohistochemistry results on tp53 M214K mutant embryos showed that although tumours are not present in untreated 2 dpf embryos yet, certain cells present in the ethmoid plate and liver have mutant p53 protein that is stable and may have escaped regulation by mdm2.
Results from immunohistochemistry, whole-mount in situ hybridization and apoptosis assay concur to indicate that the accumulation of p53 protein in zebrafish wild-type embryos, in response to p53-activating agents, is correlated with the upregulation of p53-dependent transcriptional responses. The regions that display the greatest upregulation were in the head and digestive organs, further suggesting that the induction of p53 in zebrafish and its subsequent response are tightly regulated in a tissue-specific manner. It is interesting to note that the upregulation of p53-dependent target genes is accompanied by an increase in the levels of p53 transcript. In mammals, the levels of p53 protein in a cell increase within minutes of exposure to DNA-damaging agents and this occurs through post-translational modifications of the p53 protein with no dramatic induction of p53 mRNA levels (Kastan et al., 1991) . In zebrafish, however, whole-mount in situ hybridization experiments indicated that p53 transcript levels of campthothecin-bathed, mdm2-deficient and UV-irradiated wild-type embryos were raised especially in the brain and spinal cord (Langheinrich et al., 2002) . Similarly, by using single-embryo semiquantitative reverse transcription-PCR, the levels of p53 mRNA were also found to be upregulated in wild-type embryos subjected to g-irradiation but not in homozygous tp53 M214K mutant embryos (Berghmans et al., 2005) . This indicates that perhaps in a non-mammalian system such as zebrafish, other mechanisms, besides posttranslational modification, may be at play in regulating p53 activity in response to DNA damage. Indeed our results demonstrate that p53 is itself a p53-responsive gene. Thus, although the major functions of the p53 pathway are conserved between mammals and zebrafish, differences may exist.
In conclusion, we have generated a panel of monoclonal antibodies that recognize zebrafish p53 protein.
The use of one of the antibodies, ZFp53-5.1, demonstrates that exposure to well-defined mammalian p53-activating agents does lead to p53 protein induction in zebrafish embryos, which can be detected by immunohistochemical analysis of tissues in situ. Although immunoblotting has been suggested as the benchmark for demonstrating p53 induction (Nickels et al., 1997) , our results indicate otherwise for the zebrafish system. The antibody ZFp53-5.1 is an excellent reagent for the study of p53 regulation in zebrafish and should accelerate the research using zebrafish as a model organism for high-throughput compound and genetic screening that can identify new drugs affecting the p53 pathway. Indeed the induction of tumours in p53 mutant zebrafish by human-activated oncogenes has already been established and will allow a detailed study of p53 stabilization in a cancer model (Patton et al., 2005) . Differences in the tissues that show p53 accumulation in response to different inducers imply that this system may also yield valuable information on a p53 inducing compounds bioavailability and the activity of signalling pathways. Furthermore, the size and accessibility of zebrafish embryos, as well as the high reproductive capacity of this species, makes the zebrafish model amenable to scaled-up in vivo assays for drug testing.
Materials and methods
Recombinant plasmid reconstruction
Zebrafish (Danio rerio) cDNA encoding the whole open reading frame (ORF) of p53 (PubMed database, accession number U60804) was amplified using forward (5 0 -CCGCTCG AGATGGCGCAAAACGACAGCC-3 0 ) and reverse primers (5 0 -CGGGATCCTTAATCAGAGTCGCTTCTTCC-3 0 ) with XhoI and BamHI restriction sites respectively. Amplifications were performed using Pfu enzyme (Stratagene, La Jolla, CA, USA) and inserted into the vector pET-19b (Novagen, Darmstadt, Germany) in frame with an N terminal tag of 10 histidine residues. In the resulting recombinant vector, expression of the whole ORF of His10-tagged p53 was under the control of the T7 lac operator.
Expression and purification of p53 fusion proteins Competent E. coli BL21 (DE3 lysogen) cells were transformed with recombinant vector (Novagen). The expression was estimated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis analysis (Laemmli, 1970) and the protein was purified according to the manufacturer's protocol using Ni 2 þ -charged chromatography column. The His10-tagged p53 protein was finally concentrated to 1 mg/ml and used for immunizations.
Production of the anti-p53 zebrafish antibodies BALB/c mice were immunized intraperitoneally with 100 mg of bacterial inclusion bodies of recombinant zebrafish p53 fusion protein in Freund's complete adjuvant (Sigma-Aldrich, St Louis, MO, USA). Three subsequent booster injections of 50 mg of protein were given at 2-week intervals in incomplete Freund's adjuvant (Sigma-Aldrich). The antibody titre was determined by antibody capture assay on permeabilized cells as described by Harlow and Lane (1988) . The mouse with the highest antibody titre was selected for a final boost of 10 mg of protein before being killed. Hybridoma cells were generated by fusing immune spleen cell populations with mouse SP2-0/Ag14 myeloma cells following the standard protocols (Harlow and Lane, 1988) and the recommendations of the supplier of the hybridoma isolation medium (ClonaCellt-HY, StemCell Technologies, Vancouver, BC, Canada). All anti-p53 zebrafish monoclonal antibodies were purified from ascites using protein-A and protein-G-Sepharose columns (Harlow and Lane, 1988 ) and stored at 41C.
Polyclonal anti-p53 antibody was raised by immunizing New Zealand white rabbits subcutaneously with 400 mg of zebrafish p53 fusion protein prepared as above. The first two injections were given at 2-week interval, followed subsequently by the third injection after 4 weeks. Polyclonal antisera were collected 7-9 days after the final injection when sufficiently strong reactivity was observed by immunoblotting.
Cell culture and transfection studies
The H1299 p53-null human lung carcinoma cells (Mitsudomi et al., 1992) were grown at 371C with 5% CO 2 in RPMI medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin solution (Sigma-Aldrich). Mutant p53 human cancer cell lines (BT474, T47D and BT549) and wild-type p53 human cancer cell line (MCF-7) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and 1% penicillin-streptomycin solution. For transfection purposes, H1299 cells were seeded at 1 Â 10 6 cells/ ml in 60-mm-diameter Nunclon petri dishes (Nunc, Roskilde, Denmark) to reach 80% confluence the following day. Cells were transfected with pCS-myc-Zp53, a recombinant expression vector containing the whole ORF of zebrafish p53 fused at its N terminal to a myc tag (Thisse et al., 2000) . Transfection was performed using TransFectint lipid reagent (Bio-Rad Laboratories, Hercules, CA, USA).
Screening strategy and selection of hybridoma clones A combination of antibody capture assay, immunocytochemistry, immunoblotting and plate immunoassay was used to screen the hybridoma culture supernatants. Antibody capture was performed as described previously (Harlow and Lane, 1988) on zebrafish p53-transfected H1299 cells. A mouse monoclonal antibody to c-Myc (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as positive control. Rabbit anti-mouse immunoglobulin conjugated to horseradish peroxidase (HRP) was used as secondary antibody at a dilution of 1:200. Cells were stained for peroxidase activity using Sigma FAST6 DAB (3,3 0 -diaminobenzidine tetrahydrochloride, Sigma-Aldrich).
For immunocytochemistry, H1299 cells with 80% confluence were washed with phosphate-buffered saline (PBS) and collected by trypsinization. The cells were pelleted down, washed with PBS, then fixed with 10% neutral buffered formalin (BDH, Poole, UK) and resuspended in Bacto Agar (BDH). The agar pellet was processed into paraffin wax. Sections at 5 mm were stained with primary antibody and developed as in the immunohistochemistry method in the following text.
Immunoblotting was performed by normalizing protein concentrations of the whole cell extracts using detergentcompatible Lowry reagent assay (Bio-Rad Laboratories). Proteins were separated by electrophoresis on 4-12% gradient polyacrylamide SDS gel and transferred to nitrocellulose membranes (Trans-Blot transfer medium, 0.45 mM, Bio-Rad Laboratories) using semi-dry electrophoretic transfer at 20 V for 2 h. Membranes were stained with Ponceau S to monitor equal loading before overnight incubation at 41C with hybridoma supernatants as primary antibody. Protein levels were detected using 1:1000 dilution of rabbit anti-mouse secondary antibody conjugated to HRP (DakoCytomation, Glostrup, Denmark) and enhanced chemiluminescence system (ECL Western Blotting Detection Reagents, Amersham Biosciences, Buckinghamshire, UK) followed by exposure to X-ray film (Amersham Biosciences).
Plate immunoassays were performed by coating Maxisorp 96-well microplates (Nunc) with 0.5 mg/ml recombinant zebrafish p53 fusion protein diluted in 0.1 M sodium bicarbonate buffer, pH 9.5 overnight at 41C. Plates were blocked with 5% FBS and used to screen hybridoma supernatants. The plates were developed using peroxidase-conjugated secondary antibodies and tetramethylbenzidine substrate.
Immunoprecipitation of p53 protein was performed from lysates of zebrafish p53-transfected H1299 cells as described previously . Cell extracts were pre-absorbed with protein G-Sepharose beads (GE Healthcare BioSciences, Uppsala, Sweden) before overnight incubation with purified monoclonal or polyclonal antibodies. The antibody-p53 complexes were then collected on the protein G beads before immunoblotting with appropriate antibodies.
Epitope mapping A set of overlapping synthetic peptides were synthesized (Mimotopes Pty. Ltd., Clayton, Australia) to encompass the entire zebrafish p53 ORF. This was done by designing 20-amino-acid-long peptides with 10-amino-acid overlaps with a spacer sequence (GSGS) and a biotin residue added to the N terminus of each peptide. Before using, peptides were prepared as master stock by dissolving in 80% DMSO (Sigma-Aldrich). The mapping assay was performed in streptavidin-coated Maxisorp 96-well microplates (Nunc) as described previously (Harlow and Lane, 1999) .
Pharmacological experiments on zebrafish embryos
The zebrafish tp53 M214K mutant line was obtained by targetselected mutagenesis strategy using N-ethyl-N-nitrosourea as mutagen (Berghmans et al., 2005) . Both wild-type and tp53 M214K mutant zebrafish were raised and maintained according to the standard laboratory protocols (Nusslein-Volhard and Dahm, 2002) . The embryos were reared in buffered medium (0.3 g/l sea salt) containing 0.003% 1-phenyl-2-thiourea to inhibit melanogenesis, and staged at 281C as described previously (Kimmel et al., 1995) .
To induce a p53 response, embryos were treated with p53-activating drug at 2 dpf by the addition of 50 mM R-roscovitine (Calbiochem, Bad Soden, Germany) to the buffered medium and incubated for 16 h at 281C. Controls were incubated with 0.1% DMSO. Each experiment was performed three times. Similarly, 2 dpf zebrafish embryos were given whole body g-irradiation of 24 Gy from a Gammacell s 40 Exactor (MDS Nordion, Ottawa, Canada) Caesium 137 g source at a dose rate of 1.10 Gy/min. Following this, the embryos were returned to buffered salt-water medium for 10 h before total protein extraction.
Antisense morpholino against p53 was obtained from Gene Tools (Philomath, OR, USA) with the sequence 5 0 -GCGCCATTGCTTTGCAAGAATTG-3 0 and dissolved in 1 Â Danieau solution containing 0.5% phenol red to a final concentration of 0.5 mM. Each one-cell stage embryo was injected with 1.0 nl of antisense morpholino and incubated for 2 days in buffered medium followed by drug treatment and subsequent immunohistochemistry analysis.
To prepare total embryo extracts, 3 dpf embryos were first anaesthetized in 0.003% Tricaine (ABCR GmbH, Karlsruhe, Germany) after overnight drug treatment. Embryos were rinse twice in PBS and de-yolked by pipetting up and down using a pipette tip in ice-cold PBS (10 ml/embryo) supplemented with a protease inhibitor cocktail until no visible intact embryo with yolk was observed. Centrifugation was performed at 200 g for 5 min at 41C and pelleted embryos were resuspended in whole cell lysis buffer (20 mM HEPES, pH 7.9, 280 mM KCl, 1 mM EDTA, 0.1 mM Na 3 VO 3 , 10% (v/v) glycerol, 0.7% (v/v) NP40, 20 mM NaF, 1 mM DTT). Cells were lysed by incubation on ice for 10 min followed by sonication using Microson XL 2000 (Misonix, Farmingdale, NY, USA) until the samples were uniform in consistency. The supernatant (total embryo extract) was collected by centrifugation at 20 000 g for 5 min at 41C and normalized for protein content by detergent-compatible Lowry reagent assay (Bio-Rad Laboratories) before electrophoretic separation on SDS-PAGE and immunoblotting as described above.
Immunohistochemistry on zebrafish embryos Drug-treated or g-irradiated embryos were fixed in 10% neutral buffered formalin (BDH, Poole, UK) for 1 h at room temperature followed by 41C overnight. Specimens were washed in PBST for 10 min at room temperature before embedding in 1.5% Bacto Agar (BDH), used at an embedding temperature of 601C. Specimens in agar pellets were processed into wax after dehydration in ethanol at 70% (1 h), 80% (1 h), 90% (1 h), two changes of 100% (1 h) and finally fresh 100% (4 h). The 4 h step was necessary for thorough dehydration of pellets. Specimens were then processed through three 1 h changes of xylene and finally through two changes of 601C paraffin wax (1 h) and blocked out in desired orientations. Wax sections at 5 mm were collected onto poly-L-lysine-coated slides (Menzel Glasser, Braunschweig, Germany) and dried on a 451C hot plate for 2 h.
For immunohistochemical staining, slides were dewaxed in xylene and rehydrated through a descending series of alcohols to water. Endogenous peroxidase activity was blocked by immersing sections in a solution of 3% hydrogen peroxide in methanol for 30 min. Rehydrated sections were immersed in an epitope retrieval solution (Target Retrieval Solution pH 6.0, DakoCytomation) and heated in a pressure cooker (2100 Retriever, PickCell Laboratories, Leiden, Netherlands) to expose the antigens. After overnight cooling, the slides were rinsed in three changes of PBS. Sections were blocked with 10% goat serum (DakoCytomation) in PBS. Undiluted hybridoma supernatants were used as primary antibodies for 1 h at room temperature. After a 5 min tap water wash, the sections were incubated for 30 min in the EnVision peroxidase labelled polymer conjugated to goat anti-mouse immunoglobulins (DakoCytomation). Antigen-antibody interaction was then visualized using DAB as a substrate and the sections were lightly counterstained with haematoxylin before dehydrating and mounting in DPX.
Apoptosis assay
Caspase-3 activation assay was performed using 200 mg of total embryo extract to allow reaction with 100 mM caspase-3 substrate (Z-DEVD-AMC, Molecular Probes, Eugene, OR, USA) in caspase assay buffer (10 mM PIPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 mM dithiothreitol) over a period of 2 h. The release of 7-amino-4-methylcoumarin (AMC) was measured through change in fluorescence in a fluorescence plate reader (Molecular Devices, Sunnyvale, CA, USA) with excitation at 342 nm and emission at 441 nm.
To detect apoptotic cell death on whole zebrafish, embryos were fixed overnight in 10% neutral buffered formalin followed by embedding into wax as described above. Dewaxed sections were permeabilized by incubation in freshly prepared Proteinase K (20 mg/ml in 10 mM Tris-HCl buffer) for 15 min at room temperature. TUNEL assay was performed using The In Situ Cell Death Detection Kit, TMR Red (Roche Applied Science, Mannheim, Germany) according to the manufacturer's protocol.
Whole-mount RNA in situ hybridization Probe synthesis and whole-mount RNA in situ hybridization of zebrafish embryos were performed as described previously (Jowett, 1999) . The digoxigenin-labelled sense and antisense RNA probes were generated from the following templates (Chen et al., 2005) obtained from Laboratory of Functional Genomics, Institute of Molecular and Cell Biology: bax, cyclin G1, mdm2, p21 WAF1/CIP-1 and p53. Detection of DIG probes was performed using anti-DIG antibodies coupled to alkaline phosphatase (Roche Applied Science) and colour development was visualized by Sigma FAST BCIP/NBT buffered substrate tablet (Sigma-Aldrich). Images were taken under a Leica MZ16 (Leica Microsystems, Heerbrugg, Switzerland) optics.
